Here's an interesting angle on $IBRX: traditional pharma has been locking down the cancer treatment space with conventional approaches like chemotherapy. But what if that's about to shift? The current administration's focus on immune-system-based medicine could be a game-changer. If policy tailwinds align with cutting-edge immunotherapy approaches, IBRX could see significant repricing. The stock's been held back by the old guard's grip on the industry—but once that paradigm starts cracking, you'd expect major movement. It's less about the token itself and more about whether the macro conditions finally favor innovation over tradition in medical treatment.